FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383066712> ?p ?o ?g. }

• W4383066712 endingPage "BJGP.2023.0153" @default.
• W4383066712 startingPage "BJGP.2023.0153" @default.
• W4383066712 abstract "Adverse drug reaction (ADR) related to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may negatively affect patients' treatment outcomes.To investigate the impact of ACEIs/ARBs-related ADR consultation on cardiovascular disease (CVD) events and all-cause mortality.Propensity score-matched cohort study of ACEIs/ARBs between 2004 and 2019 using UK IQVIA medical research data.ADR consultations were identified using standardised designated codes. Propensity scores were calculated based on comorbidities, concomitant medications, frailty, and polypharmacy. Cox's proportional hazard regression model was used to compare the outcomes between patients in ADR and non-ADR groups. In the secondary analysis, treatment- pattern changes following the ADR were examined and the subsequent outcomes were compared.Among 1 471 906 eligible users of ACEIs/ARBs, 13 652 (0.93%) patients had ACEIs/ARBs- related ADR consultation in primary care. Patients with ACEIs/ARBs-related ADR consultation had an increased risk of subsequent CVD events and all- cause mortality in both primary prevention (CVD events: adjusted hazard ratio [aHR] 1.22, 95% confidence interval [CI] = 1.05 to 1.43; all-cause mortality: aHR 1.14, 95% CI = 1.01 to 1.27) and secondary prevention cohorts (CVD events: aHR 1.13, 95% CI = 1.05 to 1.21; all-cause mortality: aHR 1.15, 95% CI = 1.09 to 1.21). Half (50.19%) of patients with ADR continued to use ACEIs/ARBs, and these patients had a reduced risk of mortality (aHR 0.88, 95% CI = 0.82 to 0.95) compared with those who discontinued using ACEIs/ARBs.This study provides information on the burden of ADR on patients and the health system. The findings call for additional monitoring and treatment strategies for patients affected by ADR to mitigate the risks of adverse clinical outcomes." @default.
• W4383066712 created "2023-07-05" @default.
• W4383066712 creator A5017974435 @default.
• W4383066712 creator A5024332337 @default.
• W4383066712 creator A5028633730 @default.
• W4383066712 creator A5029858865 @default.
• W4383066712 creator A5033259606 @default.
• W4383066712 creator A5074194958 @default.
• W4383066712 creator A5079644665 @default.
• W4383066712 date "2023-07-04" @default.
• W4383066712 modified "2023-10-13" @default.
• W4383066712 title "Impact of ACE Inhibitors and ARBs-related Adverse Drug Reactions Consultations on Patients’ Clinical Outcomes: A Cohort Study in UK Primary Care." @default.
• W4383066712 cites W1530264636 @default.
• W4383066712 cites W1552071134 @default.
• W4383066712 cites W1608481406 @default.
• W4383066712 cites W1671958783 @default.
• W4383066712 cites W1783190234 @default.
• W4383066712 cites W1965896168 @default.
• W4383066712 cites W1970537005 @default.
• W4383066712 cites W2016403661 @default.
• W4383066712 cites W2027228574 @default.
• W4383066712 cites W2034146561 @default.
• W4383066712 cites W2041162893 @default.
• W4383066712 cites W2051356894 @default.
• W4383066712 cites W2073313275 @default.
• W4383066712 cites W2074570166 @default.
• W4383066712 cites W2078433479 @default.
• W4383066712 cites W2107043766 @default.
• W4383066712 cites W2109198509 @default.
• W4383066712 cites W2110880027 @default.
• W4383066712 cites W2119138019 @default.
• W4383066712 cites W2126049444 @default.
• W4383066712 cites W2128043538 @default.
• W4383066712 cites W2129832544 @default.
• W4383066712 cites W2133416234 @default.
• W4383066712 cites W2152798629 @default.
• W4383066712 cites W2154031513 @default.
• W4383066712 cites W2160359845 @default.
• W4383066712 cites W2160643831 @default.
• W4383066712 cites W2168907840 @default.
• W4383066712 cites W2182000067 @default.
• W4383066712 cites W2191304082 @default.
• W4383066712 cites W2215622857 @default.
• W4383066712 cites W2291720716 @default.
• W4383066712 cites W2440694817 @default.
• W4383066712 cites W2465016211 @default.
• W4383066712 cites W2475261460 @default.
• W4383066712 cites W2570535703 @default.
• W4383066712 cites W2570609296 @default.
• W4383066712 cites W2592164257 @default.
• W4383066712 cites W2595226750 @default.
• W4383066712 cites W2598097718 @default.
• W4383066712 cites W2605567389 @default.
• W4383066712 cites W2754160328 @default.
• W4383066712 cites W2805838090 @default.
• W4383066712 cites W2888589263 @default.
• W4383066712 cites W2943413777 @default.
• W4383066712 cites W2979387360 @default.
• W4383066712 cites W2981215886 @default.
• W4383066712 cites W2990299601 @default.
• W4383066712 cites W2994812022 @default.
• W4383066712 cites W3015060671 @default.
• W4383066712 cites W3023529892 @default.
• W4383066712 cites W3106332280 @default.
• W4383066712 cites W3165433365 @default.
• W4383066712 cites W3202067378 @default.
• W4383066712 cites W4206944595 @default.
• W4383066712 cites W4225396975 @default.
• W4383066712 cites W4280531976 @default.
• W4383066712 cites W4282569505 @default.
• W4383066712 cites W64968528 @default.
• W4383066712 doi "https://doi.org/10.3399/bjgp.2023.0153" @default.
• W4383066712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37783509" @default.
• W4383066712 hasPublicationYear "2023" @default.
• W4383066712 type Work @default.
• W4383066712 citedByCount "0" @default.
• W4383066712 crossrefType "journal-article" @default.
• W4383066712 hasAuthorship W4383066712A5017974435 @default.
• W4383066712 hasAuthorship W4383066712A5024332337 @default.
• W4383066712 hasAuthorship W4383066712A5028633730 @default.
• W4383066712 hasAuthorship W4383066712A5029858865 @default.
• W4383066712 hasAuthorship W4383066712A5033259606 @default.
• W4383066712 hasAuthorship W4383066712A5074194958 @default.
• W4383066712 hasAuthorship W4383066712A5079644665 @default.
• W4383066712 hasBestOaLocation W43830667121 @default.
• W4383066712 hasConcept C126322002 @default.
• W4383066712 hasConcept C17923572 @default.
• W4383066712 hasConcept C197934379 @default.
• W4383066712 hasConcept C201903717 @default.
• W4383066712 hasConcept C203092338 @default.
• W4383066712 hasConcept C207103383 @default.
• W4383066712 hasConcept C36434225 @default.
• W4383066712 hasConcept C44249647 @default.
• W4383066712 hasConcept C50382708 @default.
• W4383066712 hasConcept C535046627 @default.
• W4383066712 hasConcept C71924100 @default.
• W4383066712 hasConcept C72563966 @default.
• W4383066712 hasConceptScore W4383066712C126322002 @default.

• next